Literature DB >> 31227222

Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study.

Rüdiger Klapdor1, Linn Wölber2, Lars Hanker3, Barbara Schmalfeldt2, Ulrich Canzler4, Tanja Fehm5, Alexander Luyten6, Martin Hellriegel7, Jens Kosse8, Christoph Heiss9, Peer Hantschmann10, Peter Mallmann11, Berno Tanner12, Jacobus Pfisterer13, Julia Jückstock14, Felix Hilpert15, Nikolaus de Gregorio16, Peter Hillemanns17, Sophie Teresa Fürst14, Sven Mahner14.   

Abstract

BACKGROUND: Lymph node (LN) metastasis is the most important prognostic factor in primary vulvar cancer. Assessing risk factors for the incidence and extent of LN metastases may help to select the optimal treatment strategy for each individual patient.
METHODS: In a subgroup analysis of the large multicenter AGO-CaRE-1 study we included all patients treated with radical groin dissection. Univariate and multivariate regression analyses were performed in order to detect factors associated with the prevalence and extent of nodal involvement.
RESULTS: In total, 1162 patients were analyzed. Univariate analyses detected age, ECOG as well as multiple tumor characteristics such as FIGO stage, grading, depth of invasion, tumor diameter, and (lymph)vascular space invasion to be related with the prevalence of LN metastases. Interestingly, only tumor stage, tumor diameter and depth of infiltration were found to be significantly associated with the number of LN metastases. In multivariate analysis, age (OR 1.03), lymphvascular space invasion (OR 4.97), tumor stage (OR 2.22) and depth of infiltration (OR 1.08) showed an association with the prevalence of LN metastases. Regarding the number of metastatic LNs, only tumor stage (OR 2.21) or, if excluded, tumor diameter (OR 1.02) were tested significant.
CONCLUSION: This large analysis of the multicenter AGO-CaRE-1-study identified lymphvascular space invasion, tumor stage, and depth of infiltration as factors with the strongest association regarding the prevalence of LN metastasis. Interestingly, tumor stage or, if excluded, tumor diameter were the only factors associated with the prevalence as well as the extent of LN metastases.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymph node metastases; Predictive factors; Sentinel lymph node; Vulvar cancer

Mesh:

Year:  2019        PMID: 31227222     DOI: 10.1016/j.ygyno.2019.06.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Regulatory T Cells with Additional COX-2 Expression Are Independent Negative Prognosticators for Vulvar Cancer Patients.

Authors:  Nadine Ansorge; Christian Dannecker; Udo Jeschke; Elisa Schmoeckel; Helene Hildegard Heidegger; Aurelia Vattai; Maximiliane Burgmann; Bastian Czogalla; Sven Mahner; Sophie Fuerst
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

2.  Sentinel lymph node biopsy in vulvar cancer: status, level of knowledge, and counseling in outpatient setting.

Authors:  Marlene Röttger; Hermann Hertel; Laura Kaukemüller; Lars Brodowski; Markus Flentje; Peter Hillemanns; Rüdiger Klapdor
Journal:  Arch Gynecol Obstet       Date:  2020-07-18       Impact factor: 2.344

3.  The potential risk of contralateral non-sentinel groin node metastasis in women with early primary vulvar cancer following unilateral sentinel node metastasis: a single center evaluation in University Hospital of Düsseldorf.

Authors:  Andreas Suhartoyo Winarno; Anne Mondal; Franca Christina Martignoni; Tanja Natascha Fehm; Monika Hampl
Journal:  BMC Womens Health       Date:  2021-01-12       Impact factor: 2.809

4.  Analysis of Short-Term Efficacy of Gasless Single-Port Laparoscopic Inguinal Lymphadenectomy Through Vulva Incision for Vulvar Cancer.

Authors:  Jin Ding; Piaopiao Teng; Xiaoming Guan; Yonghong Luo; Huafeng Ding; Suhua Shi; Xiufen Zhou; Guantai Ni
Journal:  Front Surg       Date:  2022-03-24

5.  Combined COX-2/PPARγ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients.

Authors:  Nadine Ansorge; Christian Dannecker; Udo Jeschke; Elisa Schmoeckel; Doris Mayr; Helene H Heidegger; Aurelia Vattai; Maximiliane Burgmann; Bastian Czogalla; Sven Mahner; Sophie Fuerst
Journal:  Diagnostics (Basel)       Date:  2021-03-10

6.  Vulvar cancer in hidradenitis suppurativa.

Authors:  T F M Vergeldt; R J B Driessen; J Bulten; T H J Nijhuis; J A de Hullu
Journal:  Gynecol Oncol Rep       Date:  2022-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.